SIV mac251 model, SHIV replication was more attenuated. Some animals exposed to 48 weekly low-dose (20 TCID 50 ) SHIV-1157ipd3N4 had transient viremia blips associated 49 with lack or delayed seroconversion. Animals with acute viremia ≥10,000 viral RNA 50 copies/ml seroconverted. This finding was reminiscent of an earlier study suggesting to 51 continue challenges until a threshold of ≥10,000 viral RNA copies/ml is surpassed to 52 achieve seroconversion, one criterion of HIV diagnosis. All animals exposed weekly with 53 higher doses (>10 4 TCID 50 ) of SHIV-1157(QNE)Y173H or SHIV CH505 375h.dCT 54 developed persistent infection with high peak viremia and seroconverted. Chronic 55 viremia varied widely in all three SHIV infection models. Thus, although R5 clade C 56 SHIVs are excellent tools to study prevention of virus acquisition, secondary virological 57 outcomes of vaccine efficacy (e.g. risk of infection per exposure, modulation of peak 58
The successful implementation of antiretroviral therapy (ART) for HIV-infected 81 women has resulted in a dramatic reduction of mother-to-child transmission of HIV-1 in 82 the last two decades. Yet, globally, between 400 to 500 infants acquire HIV every day 83
(1). The majority of these infections occur during the breastfeeding period. Limited 84 access to ART in rural communities, HIV diagnosis late in pregnancy, gaps in linking 85 antenatal care with postnatal mother and infant care, acute infection of the mother 86 during the breastfeeding period, and lack of ART adherence continue to impede the 87 prevention of HIV transmission via breast milk (2-9). Transmission of HIV can occur 88 throughout the entire breastfeeding period, with a cumulative risk increase with every 89 month of breastfeeding (10) (11) (12) (13) . In many resource-limited countries, breast milk remains 90 a necessary choice of nutrition and passive immunity to protect the infant against the 91 many other pathogens that are highly prevalent in these areas (6, 7, 14) . Indeed, early 92 weaning is associated with increased infant mortality (15) (16) (17) , and the WHO 93 recommends exclusive breastfeeding for 6-12 months for HIV-exposed infants (18) . 94 Therefore, the development of an HIV vaccine that can protect infants remains a high 95 priority. 96 Importantly, whereas infants born to mothers with known HIV-positive status are 97 tested at birth and immediately started on ART if HIV-positive, infants that acquire HIV 98 by breastfeeding often go undiagnosed until routine HIV testing after the cessation of 99 breastfeeding or when they develop clinical symptoms. Considering that the 100 breastfeeding period coincides with the time of rapid development of both the immune 6 system and the central nervous system, prolonged HIV replication prior to diagnosis 102 may severely interfere with multiple aspects of normal development and impede 103 immune reconstitution after ART initiation. Thus, to prevent long-term health sequelae, 104
we need a deeper understanding of the factors controlling HIV pathogenesis and 105 persistence in infants. 106
Animal models of pediatric HIV infection are an invaluable resource for 107 addressing these questions. The oral SIV mac251 infection model in infant rhesus 108 macaques simulates the most important aspects of HIV acquisition by breastfeeding in 109 human infants (19) . The pediatric SIV mac251 infection model has been extensively utilized 110 to study early host responses (20) (21) (22) (23) (24) , test new treatment strategies (25) (26) (27) , and to 111 optimize pediatric HIV vaccine strategies (28) (29) (30) (31) (32) . To further increase the translational 112 value of the pediatric oral SIV mac251 infection model, the single high-dose challenge has 113 been replaced by a repeated weekly oral SIV mac251 exposure model to more closely 114 resemble actual HIV exposures in human infants (33) (34) (35) . 115
In HIV vaccine design, the induction of protective HIV Env-specific antibody 116 responses has taken center stage. As passive immunization studies in NHP models 117 have shown that broadly neutralizing antibodies (bnAbs) can prevent infection, one 118 major goal is the development of vaccines that induce such bnAbs and could protect 119 against the various distinct HIV clades circulating worldwide. In the RV144 HIV vaccine 120 trial in human adults, however, antibodies with Fc-mediated effector function contributed 121 to the protection against HIV acquisition (36). To evaluate HIV Env-specific antibody 122 responses in nonhuman primate models, chimeric SIV/HIV Env (SHIV) challenge 123 viruses and infection models are needed. Although multiple SHIVs carrying HIV-1 7 envelopes have been developed previously, these earlier SHIVs were not characteristic 125 of clinically relevant transmitted/ founder (T/F) viruses and sometimes exhibited CXCR4 126 tropism (37, 38) . The current study took advantage of ongoing pediatric vaccine studies 127 in our groups that utilized different SHIVs as challenge virus. Towards the goal of 128 developing a clinically relevant clade C SHIV infection model to study HIV pathogenesis 129 as well as vaccine and cure strategies directed towards the pediatric population, we 130 specifically tested SHIV-1157ipd3N4, SHIV-1157(QNE)Y173H, and SHIV CH505 131 8 model (20) was subsequently refined to simulate the repeated HIV exposure of human 148 infants by breast milk by bottle-feeding SIV mac251 to neonatal macaques 3 times per day 149 for 5 consecutive days (31). This regimen resulted in systemic SIV infection in >80% of 150 infants within 2 weeks after the first exposure, but had the drawback that, as 151 inoculations were all provided in a narrow time window, it was not possible to identify 152 which inoculation induced infection (21, 28) . We subsequently developed a repeated 153 weekly oral SIV mac251 exposure model (33) (34) (35) . The virological outcome of this repeated 154 weekly challenge strategy was highly consistent; in studies spanning 3 years, the 155 estimated risk of infection per exposure ranged from 0.23-0.25 (33-35). Animals 156 exhibited high peak viremia (median: 4.8x10 7 copies/ ml) and viremia persisted at high 157 levels (at week 8 post-infection [PI]: median: 1.1x10 7 copies/ ml) ( Figure 1 ). This oral 158 SIV mac251 infection model in infant macaques best recapitulates the outcome of HIV-159 infected human infants that progress rapidly to AIDS in the absence of ART. 160
The reproducibility of the oral pediatric SIV mac251 infection model constitutes a 161 fundamental value for the study of pediatric HIV. However, as with any animal model, 162
and dependent on the purpose of the study, certain limitations may apply. In 163 transmission studies, the evaluation of T/F viruses is hampered by the limited genetic 164 diversity. Although SIV mac251 is an uncloned viral swarm, the genetic diversity within 165 each stock is often low and variable among different SIV mac251 challenge stocks 166 because of prior histories of propagation (22, 34, 45) . In addition, due to significant 167 differences in envelope between SIVmac (which is similar to HIV-2) and HIV-1, the use 168 of the oral pediatric SIV mac251 infection model also has limited translational potential for 169
HIV vaccine studies assessing the role of HIV Env-specific antibody responses in 170 vaccine-mediated protection against HIV acquisition. Therefore, we aimed to develop 171 novel oral SHIV C infection models. Analogous to the pediatric SIV mac251 infection 172 model, we tested 3 different SHIVs in a repeated, weekly oral SHIV exposure model 173 with the goal to achieve an infection risk of 25% to 50% per exposure in infant 174 macaques. Virus was applied atraumatically in 1 ml volume to the oral mucosa and 175 animals were considered systemically infected when plasma viral RNA was detected at 176 two consecutive time points. pathogenicity (41, 46, 47) . Furthermore, the SIV mac239 LTR was engineered to contain 185 additional NF-B sites (48). We selected the clone SHIV-1157ipd3N4 for our studies 186 because it was able to infect adult macaques by multiple mucosal routes, including the 187 oral route (49) . 188
Based on data in adult macaques (49), we tested a dose of 800 TCID 50 SHIV-189 1157ipd3N4 in infant macaques. All infant macaques (n=3) became infected after a 190 single oral exposure ( Figure 2A ). We then exposed a second group of 4 infant 191 macaques to only 10 TCID 50 of SHIV-1157ipd3N4. Plasma viremia became detectable 192 in 2 of the 4 infants after 3 challenges and these 2 infants received no further oral SHIV 193 exposures ( Figure 2B ). The remaining 2 infant macaques developed viremia after the 194 dose for the 4 th exposure was increased to 50 TCID 50 of SHIV-1157ipd3N4 ( Figure 2B ). 195
Based on this initial virus titration, we proceeded with a weekly oral exposure 196 regimen of 20 TCID 50 in 7 infant macaques starting at week 6 of age (50). Five of 7 197 SHIV-1157ipd3N4 infected infant macaques developed high peak viremia (>10 6 viral 198 RNA copies/ ml) that subsequently declined at variable levels ( Figure 2C ). The risk of 199 infection per oral exposure (0.21) in these 5 infant macaques was comparable to the 200 oral SIV mac251 infection model (50). The other two infants (#46040, #46048) had only 201 transient viremia. One of these infant macaques tested positive for 5700 viral RNA 202 copies /ml plasma after the first exposure and viral RNA was still detectable at the next 203 time point, although at very low levels of only 25 copies/ ml ( Figure 2C ). Therefore, 204 based on our criteria that an animal would be considered infected when viral RNA was 205 detectable at two consecutive time points, this animal received no further challenges. In 206 contrast to these 6 infants, the remaining animal (#46048) remained viral RNA negative 207 after 7 exposures to 20 TCID 50 of SHIV-1157ipd3N4 ( Figure 2C ). Therefore, the dose 208 was increased to 40 TCID 50 of SHIV-1157ipd3N4, and a single plasma viral RNA "blip" 209 of 450 copies /ml was detected after 2 challenges ( Figure 2C ); viral RNA was not 210 detected at any later time point. Consistent with our infection criteria, we considered this 211 animal uninfected after a total of 13 (7x20 TCID 50 plus 6x40 TCID 50 ) weekly SHIV-212 1157ipd3N4 challenges (50). Reduced viremia or lack of persistent viremia, as 213 previously reported, was not associated with protective MHC or TRIM5 genotypes (50), 214 but instead was likely the result of the very low exposure dose, a dose 100x lower than 215 the dose in the repeated oral SIV mac251 challenge model. This conclusion is indirectly 216
An oral SHIV CH505 375H.dCT infection model in infant macaques 240 241
The HIV Env in SHIV CH505 375H.dCT, similar to SHIV-1157ipd3N4, is also 242 derived from a clade C, R5-tropic T/F virus with a tier 2 neutralization phenotype, 243
although it was isolated from an adult HIV-infected patient who developed broadly 244 neutralizing activity (54). Recognizing the differences in the interactions of HIV Env or 245 SIV Env with the rhesus CD4 molecule, the HIV env gene was mutated at position 375 246 to enhance binding to rhesus CD4, thereby increasing pathogenicity in rhesus 247 macaques (40). In adult macaques, CH505 375H.dCT was infectious by the intravenous 248 (IV), intravaginal (IVAG), and intra-rectal (IR) route (Dr. Shaw, pers. comm.) . 249
To determine an oral infectious CH505 375H.dCT dose in infant macaques, we 250 titrated the virus in vivo starting with a 1:80 dilution (equal to 8.5x10 4 TCID 50 /ml) of the 251 virus stock. The first animal remained uninfected after 6 weekly oral exposures to 252 CH505 375H.dCT ( Figure 4A ). The oral challenge dose was then increased weekly 253
(1:40, 1:20, 1:10, 1:5, and 1:2) until the animal eventually became infected after 5 254 exposures to undiluted virus (6.8x10 6 TCID 50 /ml; Figure 4A ). A second animal, 255 however, became infected after a single exposure to 8.5x10 4 TCID 50 /ml of CH505 256 375H.dCT, whereas two additional animals remained uninfected after two challenges, 257 but became viremic after a single exposure to 17x10 4 TCID 50 /ml ( Figure 4B ). 258
A second group of infant macaques (n=6) at 4 weeks of age was exposed via 259 bottle-feeding 3 times daily at a dose of 8.5x10 4 TCID 50 /ml for 5 consecutive days, a 260 regimen we had successfully used with SIV mac251 to simulate repeated exposure to HIV 261 by breastfeeding (21, 28) . However, only one of the infants became infected using this 262 13 exposure regimen and had a low plasma viremia of 40 copies/ml at week 1 after the first 263 exposure ( Figure 4C ). Therefore, and based on the challenge outcome in the first group 264 of infant macaques, we decided to challenge the uninfected animals of the second 265 group once weekly with 6.8x10 5 TCID 50 /ml SHIV CH505 375H.dCT. Applying this 266 regimen, 2 animals became infected after 1 exposure, and 1 animal each at 2 or 3 267 exposures ( Figure 4C ). We then increased the exposure dose and the last animal 268 became infected after two oral exposures of 3.4x10 6 TCID 50 /ml SHIV CH505 375H.dCT 269 ( Figure 4C ). Independent of the dose required to infect the animals, all animals viremia, seroconversion occurred within the first 2-4 weeks of SHIV CH505 375H.dCT 283 infection ( Figure 6 ). The magnitude of plasma gp120-specific IgG antibodies appeared 284 to be higher in SHIV CH505 375H.dCT (range from 10 4 -10 6 ng/ml) compared to SHIV-285 1157ipd3N4 (maximum of 10 5 g/ml) infected infant macaques, but as we only followed 286 the infection for 8 weeks PI, it is possible that maximum plasma gp120-specific IgG 287 antibody levels in some animals had not been reached at this time point. 288
289
We also observed an age-related decrease in the CD4:CD8 T cell ratio prior to 290 oral SHIV CH505 375H.dCT exposure ( Figure 6 ). While the CD4:CD8 T cell ratio 291 continued to decline in 2 of the 6 SHIV CH505-infected animals, the CD4:CD8 T cell 292 ratio remained relatively stable in the remaining 4 infants and by 8 weeks PI, the median 293
CD4:CD8 T cell ratio had decreased by 11% (range: 0% to 23%; Figure 5 ). There was 294 no apparent correlation between the magnitude of virus replication and the decline of 295 the CD4:CD8 T cell ratio in either of the SHIV infection models. However, due to the 296 short follow-up time, we could not assess whether continuous virus replication would 297 have resulted in a more pronounced CD4 + T cell decline over time. In previous studies evaluating pediatric vaccine candidates intended to prevent 308 breast milk transmission of HIV in human infants, we employed the repeated oral 309 SIV mac251 exposure model in infant macaques (33) (34) (35) . Consistent behavior of the 310 SIV mac251 challenge virus is a strength of that model; in multiple studies the risk of 311 infection per SIV mac251 exposure, peak viremia, as well as chronic viremia were highly 312 similar among all animals across all studies (33) (34) (35) . These findings provided the basis 313 for the development of the repeated oral SHIV exposure models. Our results 314 demonstrate that all three SHIVs could infect infant macaques via repeated oral 315 exposure. Therefore, all three SHIVs qualify as challenge models to evaluate pediatric 316 vaccines for their ability to protect against virus acquisition, the ultimate goal of an HIV 317 vaccine. 318 319 NHP models for HIV/AIDS should reflect the biology of HIV-1 transmission in 320 humans as closely as possible to maximize the predictive value of NHP vaccine safety 321 and efficacy for testing of HIV vaccine candidates in humans. People enrolled in such 322 trials may not have the same close follow-up that can be applied in NHP studies, where 323 viral RNA loads are measured once or twice a week. As a consequence, vaccine 324 efficacy in clinical trials is assessed mostly by seroconversion. In HIV-exposed infants, 325 the presence of maternal antibodies may prevent the use of seroconversion as a clinical 326 read-out. The generation of specific antiviral antibodies takes several weeks in HIV-327 infected humans as well as in rhesus macaques infected with either SIV or SHIV. 328 Therefore, in NHP challenge models of repeated SIV/SHIV exposure, it is not practical 329 to apply seroconversion as readout; instead, the primary readout is viremia. The highly 330 reproducible viral outcome of the repeated oral SIV mac251 challenge model validates the 331 use of viremia as readout for vaccine efficacy. However, the results of the various SHIV 332 exposure models described here emphasize the need to define stringent criteria of 333 infection when outcome measures other than viremia are utilized to assess vaccine 334 efficacy. 335
336
In the current study, based on our findings in the repeated oral SIV mac251 337 exposure model, we had defined infection as two consecutive viral RNA positive time 338 points. Applying this criterion, 1 of 7 SHIV-1157ipd3N4-exposed animals that showed a 339 single post-challenge viral blip was considered uninfected. The remaining 6 SHIV-340 1157ipd3N4-exposed infants were considered infected, although one of these animals 341 only had transient viremia. As discussed above, in human vaccine trials, weekly 342 measurements of viremia in real time are not feasible, and viral blips as observed in 2 of 343 7 SHIV-1157ipd3N4-exposed infant macaques, would likely be missed. The fact that 344 these two animals also exhibited delayed or no seroconversion, further confirmed this 345 conclusion. In contrast, SHIV-1157ipd3N4-exposed animals with high peak viremia 346 (>10 6 copies/ ml) in the acute phase, seroconverted rapidly. This result is remarkably 347 similar to the outcome of the clade C SHIV-2873Nip intrarectal challenge in adult 348 macaques (55). The former study established that viremia below 10 4 copies of viral 349 RNA/ml was insufficient to result in seroconversion. Therefore, to achieve "persistent This variability in chronic viremia is reminiscent of earlier SHIVs, such as the clade B 366
Env SHIV SF162P3 or SHIV-BaLP4 (56, 57). Our results further suggest that the 367 modifications introduced to SHIV-1157ipd3N4, SHIV-1157(QNE)Y173H, or SHIV 368 CH505 375H.dCT by in vivo passage and/or specific genetic manipulation to increase 369 the pathogenicity in rhesus macaques may have increased peak viremia, but were less 370 efficient in establishing persistent high-level chronic phase viremia. The lack of 371 persistent high viremia, as is generally observed in ART-naïve HIV-infected human 372 infants, and is recapitulated in the pediatric SIV mac251 rhesus macaque infection model, 373
but not with the present SHIVs represents a limitation of these SHIV viruses. However, 374 the variability in chronic SHIV-1157ipd3N4, SHIV-1157(QNE)Y173H, or SHIV CH505 375 375H.dCT viremia is also observed in adult macaques (39, 49, 58) , indicating that not 376 necessarily age, but other, additional viral and/or host-derived factors constrained the 377 replication of the two tested SHIVs in rhesus macaques. Attenuated virus replication 378 was also observed after intrarectal challenge of adult macaques with SHIV BG505 (59). 379
380
We want to reiterate that prevention of infection is the primary goal of an effective 381 HIV vaccine. However, a vaccine that cannot prevent infection could potentially be of 382 clinical importance if disease can be ameliorated and/or transmission of HIV can be 383 significantly reduced. In fact, the analysis of the most recent human HIV vaccine trials, 384
including the RV144 trial, added viral load as co-primary readout of vaccine efficacy 385 (60). Therefore, we assessed secondary outcome measures of vaccine efficacy after 386 oral SIV or SHIV exposure. Extrapolating from those data, applying a group size of 10 387 animals in the control and vaccine arms, and assuming at most 10 exposures per 388 animal, each of the infection models would provide >80% power to observe an 80% 389 reduction in the per exposure risk of infection (Table 1) . Applying the stringent criterion 390 of systemic persistent infection being defined as plasma viremia above10 4 viral RNA 391 copies/ ml during the acute phase, the SHIV-1157ipd3N4, SHIV-1157(QNE)Y173H , or 392 the SHIV CH505 375H.dCT exposure model provide 99%, 98%, or 83% power, 393 respectively, to detect 1xlog 10 difference in peak viremia between the control and 394 vaccine group (Table 1) . The inclusion of SHIV-1157ipd3N4-infected animals with 395 transient viremia would reduce the power to only 52% (Table 1) , reiterating the 396 importance of concisely and consistently defining infection criteria in preclinical 397 nonhuman primate studies. Long-term virological outcome was not assessed in the 398 current study, but the observed attenuated nature of SHIV replication suggests that viral 399 setpoint might not be a feasible readout of vaccine efficacy in SHIV challenge models. 400
We did instead calculate the in area-under-the curve (AUC) viremia between weeks 0 401 (defined as the week prior to the first viral PCR positive time point in plasma) to 8 PI, 402 and determined that, using again group sizes of 10 animals, the SHIV-1157ipd3N4 and 403 the SHIV CH505 375H.dCT infection models would provide 99% power to detect a 1 404 log 10 difference between the control and vaccine group in AUC viremia, with somewhat 405 lower power obtainable in the SHIV-1157(QNE)Y173H model (Table 1 ). In this context, 406 it should be stressed that SIV mac251 is an uncloned isolate, whereas the three tested 407
SHIVs are all clone-derived (using the SIV mac239 clone as background) and differ 408 substantially in their design. Thus, caution is warranted for a direct head-to-head 409 comparison of these viruses. 410
411
The choice of a challenge virus and model depends on many different factors. 412
The SIV mac251 infection model would be a poor choice to evaluate the role of HIV Env-413 directed neutralizing antibodies in vaccine-mediated protection because SIV mac251 is 414 highly neutralization resistant and the SIV Env is distinct from HIV Env. In contrast, both 415 SHIV-1157ipd3N4 and SHIV CH505 375H.dCT are considered Tier 2 neutralization 416 sensitive viruses (40, 41) . In vaccine studies testing the importance of Env-specific 417 antibodies with Fc-mediated effector function, it might prove useful to start with 418 challenge viruses that share a high degree of homology in specific Env epitopes, 419
including determinants in the V1V2 and V3 regions that have been associated with 420 protection in the RV144 HIV vaccine trial in human adults (36), before testing protection 421 against a challenge virus heterologous to epitopes of the immunogen. Indeed, the 422 SHIV-1157(QNE)Y173H was specifically designed to better match V2 regions of 423 immunogens and improve recognition by neutralizing antibodies in a vaccine study (39) . Research Institute, San Antonio, TX). We prepared a virus stock by growing 463
SHIV1157ipd3N4 in adult rhesus PBMC as described (41, (46) (47) (48) Ltd., Ness Ziona, Israel) at 10 ng/ ml, and recombinant human IL-2 (ProSpec-Tany 468
TechnoGene Ltd) at 50-100 U/ ml. An aliquot of the virus-containing culture supernatant 469 was grown in TZM-bl cells and determined to have a titer of 18,000 TCID 50 /ml. analysis (see below) of multiple serial dilutions of the virus stock yielded an average 471 value of 7.6x10 8 RNA copies/ ml. 472
To determine the infectious dose in infant macaques, we used a total of 8 473 animals at 12 weeks of age. The infant macaques that were challenged orally with 1 ml 474 20 TCID 50 of SHIV-1157ipd3N4 received their first virus exposure at 6 weeks of age and 475 continued to be orally exposed once weekly until infection was confirmed by plasma 476 viremia as described above for SIV mac251 . formalin-fixed, paraffin-embedded lymph nodes were cut and stained for CD3 and CD20 504 as previously described (22, 35) . SHIV RNA was visualized with the 1-Plex ViewRNA TM 505 ISH Tissue Assay Kit using SIV mac239 or Beta actin (positive control) probe sets that 506 were dectected via the ViewRNA TM Chromogenic Signal Amplification Kit (all from 507
ThermoFisher, Waltham, MA). These two sequential slides were indivudually imaged 508 with a Zeiss AxioObserver microscope and AxioCam MRm camera. Composite overlays 509 of CD3/CD20 stained slides with ISH slides were prepared using Zen Lite v2.3 software 510 (Zeiss). 511 512 Plasma IgG antibody responses were measured as previously described using gp120 of 513 SHIV-1157 or SHIV CH505 375H.dCT, respectively (29, 50) . 514 24 515 CD4:CD8 T cell ratios were determined based on Complete Blood Counts and CD4 + 516 and CD8 + T cell percentages measured by flow cytometry (21, 28, 33, 34) . The content is solely the responsibility of the authors and does not necessarily 536 represent the official views of the National Institutes of Health. 537
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The x-axis refers to the age of the animal in weeks. Virus exposure began at 6 weeks of 582 age and plasma viremia is illustrated by the black line with black triangles. The induction 583 of gp120-specific plasma IgG antibodies in response to infection is indicated by the line 584 with grey diamond symbols, with antibody measurements starting at week 6, the time of underneath the x-axis. Panel C: Plasma viremia of 6 infant macaques that were 594 exposed to SHIV CH505 375H.dCT 3x/day for 5 days (each dose at 8.5x10 4 TCID 50 /ml), 595 and subsequently underwent a once weekly oral challenge with SHIV CH505 starting at 596 6.8x10 5 TCID 50 /ml dilution. In each panel, the x-axis displays the number of oral virus Figure 3 , except that the oral challenge with CH505 375H.dCT was started 614 at week 9 of age (see Figure 4C ). 
